JAMES B ROTTMAN
Veterinary in North Sudbury, MA
License number
Massachusetts 4707
Issued Date
Jul 14, 1997
Expiration Date
Feb 28, 2017
Type
Veterinarian
Address
Address
North Sudbury, MA 01776
Professional information
Modulation Of Systemic Memory T Cell Trafficking
US Patent:
2005016, Aug 4, 2005
Filed:
Feb 17, 2005
Appl. No.:
11/061052
Inventors:
Eugene Butcher - Portola Valley CA, US
James Campbell - Weymouth MA, US
Lijun Wu - Lexington MA, US
James Rottman - Sudbury MA, US
James Campbell - Weymouth MA, US
Lijun Wu - Lexington MA, US
James Rottman - Sudbury MA, US
International Classification:
G01N033/567, A61K039/395
US Classification:
424143100, 435007210
Abstract:
Methods are provided to specifically modulate the trafficking of systemic memory T cells, particularly CD4+ T cells, without affecting naive T cells or intestinal memory T cells. It is shown that systemic memory T cells, which are characterized as CD45Ra, and integrin α4β7, express high levels of CCR4. Ligands of CCR4, such as TARC or MDC, act as an adhesion trigger, wherein upon CCR4 binding, these cells undergo integrin-dependent arrest to the appropriate vascular receptor(s). This arrest acts to localize the cells at the target site. The methods of the invention manipulate this triggering, and CCR4 mediated chemotaxis, to affect the localization of T cells in targeted tissues. In one embodiment of the invention, the active agent is a CCR4 agonist, that acts to enhance T cell localization. In an alternative embodiment, the agent is an antagonist that blocks CCR4 biological activity. An advantage of the invention is the selectivity for systemic memory T cells, without affecting native T cells or intestinal memory T cells.
Modulation Of Systemic Memory T Cell Trafficking
US Patent:
6881406, Apr 19, 2005
Filed:
Apr 17, 2001
Appl. No.:
09/837446
Inventors:
Eugene C. Butcher - Portola Valley CA, US
James J. Campbell - Palo Alto CA, US
Lijun Wu - Reading MA, US
James B. Rottman - Sudbury MA, US
James J. Campbell - Palo Alto CA, US
Lijun Wu - Reading MA, US
James B. Rottman - Sudbury MA, US
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
Millennium Pharmaceuticals, Inc. - Cambridge MA
Millennium Pharmaceuticals, Inc. - Cambridge MA
International Classification:
A61K039/395
US Classification:
4241301, 4241331, 4241371, 4241411, 4241431, 4241441, 4241521, 4241531, 4241541, 4241841
Abstract:
Methods are provided to specifically modulate the trafficking of systemic memory T cells, particularly CD4+ T cells, without affecting naive T cells or intestinal memory T cells. It is shown that systemic memory T cells, which are characterized as CD45Ra, and integrin α4β7, express high levels of CCR4. Ligands of CCR4, such as TARC or MDC, act as an adhesion trigger, wherein upon CCR4 binding, these cells undergo integrin-dependent arrest to the appropriate vascular receptor(s). This arrest acts to localize the cells at the target site. The methods of the invention manipulate this triggering, and CCR4 mediated chemotaxis, to affect the localization of T cells in targeted tissues. In an alternative embodiment, the agent is an antagonist that blocks CCR4 biological activity. An advantage of the invention is the selectivity for systemic memory T cells, without affecting native T cells or intestinal memory T cells.
Tango 197 And Tango 216 Compositions And Methods
US Patent:
2003013, Jul 17, 2003
Filed:
Dec 20, 2001
Appl. No.:
10/038307
Inventors:
James Rottman - Sudbury MA, US
Theresa O'Keefe - Waltham MA, US
Engin Ozkaynak - Milford MA, US
Judith Healey - Newton MA, US
Theresa O'Keefe - Waltham MA, US
Engin Ozkaynak - Milford MA, US
Judith Healey - Newton MA, US
International Classification:
A61K038/36, A61K038/17
US Classification:
514/012000
Abstract:
The present application relates, in part, to methods and compositions for the prevention or amelioration of symptoms of anthrax. In particular, the present invention relates to TANGO 197 and/or TANGO 216 fusion polypeptides and their use as part of such methods.
Tango 197 And Tango 216 Compositions And Methods
US Patent:
2003014, Jul 31, 2003
Filed:
Jul 24, 2002
Appl. No.:
10/201292
Inventors:
James Rottman - Sudbury MA, US
Theresa O'Keefe - Waltham MA, US
Engin Ozkaynak - Milford MA, US
Judith Healey - Newton MA, US
Theresa O'Keefe - Waltham MA, US
Engin Ozkaynak - Milford MA, US
Judith Healey - Newton MA, US
International Classification:
A61K038/36, A61K039/02
US Classification:
514/012000, 424/190100
Abstract:
The present application relates, in part, to methods and compositions for the prevention or amelioration of symptoms of anthrax. In particular, the present invention relates to TANGO 197 and/or TANGO 216 fusion polypeptides and their use as part of such methods.
Aptamer Therapeutics Useful In The Treatment Of Complement-Related Disorders
US Patent:
8436164, May 7, 2013
Filed:
Jun 18, 2012
Appl. No.:
13/525680
Inventors:
Claude Benedict - Cambridge MA, US
David Epstein - Huntington NY, US
Charles Wilson - Concord MA, US
Dilara McCauley - Cambridge MA, US
Jeffrey Kurz - Winchester MA, US
Markus Kurz - Basel, CH
Thomas Greene McCauley - Cambridge MA, US
James Rottman - Sudbury MA, US
David Epstein - Huntington NY, US
Charles Wilson - Concord MA, US
Dilara McCauley - Cambridge MA, US
Jeffrey Kurz - Winchester MA, US
Markus Kurz - Basel, CH
Thomas Greene McCauley - Cambridge MA, US
James Rottman - Sudbury MA, US
Assignee:
Archemix LLC - San Francisco CA
International Classification:
C07H 21/04
US Classification:
536 245
Abstract:
The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.
Methods And Compositions For The Diagnosis And Treatment Of Demyelinating Inflammatory Disorders
US Patent:
2004000, Jan 1, 2004
Filed:
Jun 26, 2002
Appl. No.:
10/186381
Inventors:
James Rottman - Sudbury MA, US
Richard Kroczek - Berlin, DE
Richard Kroczek - Berlin, DE
International Classification:
A61K038/20, A61K039/395, A61K031/573, A61K031/4745, G01N033/567
US Classification:
424/146100, 424/085200, 435/007210, 514/011000, 514/171000, 514/291000
Abstract:
The present invention provides methods of suppressing demyelinating inflammatory disorders in a patient by administering to the patient a compound that inhibits binding of B7RP-1 to ICOS or inhibits signaling through the B7RP-1 pathway. Various therapeutic regimens are provided. Methods of identifying such compounds are also provided. The present invention further provides kits and pharmaceutical compositions useful in the present methods.
Aptamer Therapeutics Useful In The Treatment Of Complement-Related Disorders
US Patent:
8236773, Aug 7, 2012
Filed:
Feb 14, 2006
Appl. No.:
11/884411
Inventors:
Claude Benedict - Cambridge MA, US
David Epstein - Huntington NY, US
Charles Wilson - Concord MA, US
Dilara McCauley - Cambridge MA, US
Jeffrey Kurz - Winchester MA, US
Markus Kurz - Basel, CH
Thomas Greene McCauley - Cambridge MA, US
James Rottman - Sudbury MA, US
David Epstein - Huntington NY, US
Charles Wilson - Concord MA, US
Dilara McCauley - Cambridge MA, US
Jeffrey Kurz - Winchester MA, US
Markus Kurz - Basel, CH
Thomas Greene McCauley - Cambridge MA, US
James Rottman - Sudbury MA, US
Assignee:
Archemix LLC - San Francisco CA
International Classification:
C12N 15/11
US Classification:
514 44A
Abstract:
The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.
Aptamer Therapeutics Useful In The Treatment Of Complement-Related Disorders
US Patent:
2013023, Sep 12, 2013
Filed:
Mar 4, 2013
Appl. No.:
13/783633
Inventors:
David Epstein - Huntington NY, US
Charles Wilson - Concord MA, US
Dilara McCauley - Cambridge MA, US
Jeffrey Kurz - Winchester MA, US
Markus Kurz - Basel, CH
Thomas Greene McCauley - Cambridge MA, US
James Rottman - Sudbury MA, US
Charles Wilson - Concord MA, US
Dilara McCauley - Cambridge MA, US
Jeffrey Kurz - Winchester MA, US
Markus Kurz - Basel, CH
Thomas Greene McCauley - Cambridge MA, US
James Rottman - Sudbury MA, US
Assignee:
ARCHEMIX LLC - San Francisco CA
International Classification:
A61K 47/48
US Classification:
514 44 R, 536 231
Abstract:
The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.
Aptamer Therapeutics Useful In The Treatment Of Complement-Related Disorders
US Patent:
7803931, Sep 28, 2010
Filed:
Feb 14, 2005
Appl. No.:
11/058134
Inventors:
Claude Benedict - Cambridge MA, US
John Diener - Cambridge MA, US
David Epstein - Belmont MA, US
Dilara Grate - Cambridge MA, US
Sara Chesworth Keene - Tewksbury MA, US
Jeffrey Kurz - Arlington MA, US
Markus Kurz - Newton MA, US
Thomas Greene McCauley - Cambridge MA, US
James Rottman - Sudbury MA, US
Kristin Thompson - Arlington MA, US
Charles Wilson - Concord MA, US
Anna J. Zoltoski - South Boston MA, US
John Diener - Cambridge MA, US
David Epstein - Belmont MA, US
Dilara Grate - Cambridge MA, US
Sara Chesworth Keene - Tewksbury MA, US
Jeffrey Kurz - Arlington MA, US
Markus Kurz - Newton MA, US
Thomas Greene McCauley - Cambridge MA, US
James Rottman - Sudbury MA, US
Kristin Thompson - Arlington MA, US
Charles Wilson - Concord MA, US
Anna J. Zoltoski - South Boston MA, US
Assignee:
Archemix Corp. - Cambridge MA
International Classification:
C07H 21/04
US Classification:
536 245
Abstract:
The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.
Ferroportin Antibodies And Methods Of Use
US Patent:
2011027, Nov 10, 2011
Filed:
Jan 23, 2009
Appl. No.:
12/863737
Inventors:
Tara Arvedson - Simi Valley CA, US
James Rottman - Sudbury MA, US
Barbra Sasu - Westlake Village CA, US
Gregory Dyas - Carnel IN, US
James Rottman - Sudbury MA, US
Barbra Sasu - Westlake Village CA, US
Gregory Dyas - Carnel IN, US
International Classification:
A61K 39/395, C07H 21/00, C12N 15/63, C12N 5/10, C12N 1/21, C12N 1/15, C12N 1/19, C12P 21/00, G01N 33/577, A61P 3/00, A61P 7/06, A61P 9/04, A61P 13/12, A61P 3/10, A61P 19/02, A61P 9/10, A61P 35/00, A61P 7/00, A61P 29/00, A61M 37/00, C07K 16/18
US Classification:
4241391, 5303879, 5303873, 536 2353, 4353201, 435331, 435419, 4352523, 43525231, 43525234, 43525235, 43525233, 43525411, 4352542, 43525421, 43525422, 43525423, 4352546, 4352544, 4352545, 4352543, 435 696, 436501, 435 721, 604500
Abstract:
Compositions for treating disorders of iron homeostasis are provided. More particularly, anti-ferroportin antibodies, compositions containing such antibodies, corresponding nucleic acids, vectors and host cells, and methods of making such antibodies are provided.